Detected ·
Leal Therapeutics
$30M—
Leal Therapeutics announces $30M Series financing and initiates a Phase 1b/2a clinical trial for LTX-001, an oral GLS1 inhibitor for schizophrenia.
- Website
- lealtx.com
- Amount
- $30 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-19 08:16:38 UTC
- Signal ID
- 3fc3690f-e215-4fcc-839b-cbb57523afac
As the API returns it
{
"id": "3fc3690f-e215-4fcc-839b-cbb57523afac",
"created_at": "2026-08-19T08:16:38.648143Z",
"company_name": "Leal Therapeutics",
"company_website_url": "lealtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/leal-therapeutics",
"event_type": "funding",
"funding_amount": 30000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Leal Therapeutics announces $30M Series financing and initiates a Phase 1b/2a clinical trial for LTX-001, an oral GLS1 inhibitor for schizophrenia.*"
}